GSK (GSK.L)

GSK's price jumped about 4% in the past week, its sharpest move in a while.

What is going on right now?

The share price has been climbing steadily and now sits above where it was over the past month or two, though still below its longer-term trend from the past year. Separately, UK inflation came in at 3.5%, and a weaker pound may affect broader confidence on the London market.

How is the business itself doing?

GSK makes vaccines like Shingrix and RSV shots, plus treatments for HIV and cancer, employing nearly 67,000 people. Revenue grew about 5%, but reported earnings dropped sharply, by roughly 70%.

What stands out?

GSK keeps about 73 cents of every pound of sales after production costs, which is unusually high. Still, its earnings fell hard, and its short-term cash cushion sits below what it owes in the near term.

What comes next?

GSK's next results are due October 28, and how its US vaccine sales and pricing hold up will show whether that earnings drop was a one-quarter stumble or something stickier.